associated with colorectal and other cancers in the hereditary nonpolyposis colorectal syndrome (HNPCC), as well as a proportion of sporadic colorectal cancers (Lairmore and Norton, 1997) . Mutational inactivation of both copies of DNA MMR genes results in a profound repair defect which is presumed to lead to progressive accumulation of secondary mutations throughout the genome, some of which affect important growth regulatory genes and hence give rise to cancer (Peltomaki and de la Chapelle, 1997) .
The protein products of MMR genes (MSH2, MLH1, PMS1, PMS2, GTBP or MSH6) act in concert as part of complexes to enable the recognition and excision of mis-or unmatched bases. MSH2 and MLH1 proteins are vital, which may explain why the majority of HNPCC mutations occur in either MSH2 or MLH1 (Frayling, 1999) . MMR plays an important role in maintaining replication fidelity, processing and regulating recombination (Kolodner, 1995) . Mutation in any of the genes required to maintain the integrity of the genome will result in a state of genetic instability, a 'mutator' phenotype, which could contribute to the accumulation of mutations required for multistage carcinogenesis (Loeb, 1991 (Loeb, , 1994 .
Microsatellites are stably inherited short tandem repeat DNA sequences that are unique to each individual (Brentnall, 1995) . Microsatellite instability (MSI) appears as aberrant-sized alleles resulting from a gain or loss of short repeat units in tumour DNA in comparison to normal DNA. MSI serves as a useful marker of a mutator phenotype (Peltomaki, 1997) which is a characteristic of HNPCC and reflects malfunctions in the replication or repair of DNA . Biochemical studies have provided a link between MSI and defective MMR . In addition to HNPCC, MSI has been observed in several sporadic tumours (Han et al, 1993;  Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer Chong et al, 1994; Wada et al, 1994; Speicher, 1995) . Several studies have reported the occurrence of MSI in bladder cancer (Gonzalez-Zulueta et al, 1993; Mao et al, 1994 Mao et al, , 1996 Orlow et al, 1994; Uchida et al, 1996; Steiner et al, 1997; Christensen et al, 1998; Mourah et al, 1998) . Recently, the tumour spectrum associated with germline mutations of MMR genes in HNPCC cases was found by Aarnio et al (1999) to involve several organs including the uro-epithelium. These studies may point to the possibility of involvement of mismatch repair genes in sporadic bladder cancer, thus the authors were interested in assessing MMR status in bladder cancer in the context of quantitative expression and detection of microsatellite instability at the regions of the MMR genes: MSH2 and MLH1.
MATERIALS AND METHODS

Samples
Fifty seven bladder tumour samples (44 TCC and 13 SCC) were obtained from radical cystectomy specimens from the Department of Urology, Faculty of Medicine, Alexandria University. The patients' mean age was 56.7 ± 8.6 years (ranging from: 38-71 years). Forty three patients were male (75%) and 14 were female (25%). Sixty eight percent of patients (39/57) self-reported a history of either a positive test (presence of bilharzial eggs in urine) or past treatment for schistosomiasis. Tissues collected included grossly obvious tumour tissue that was confirmed by subsequent histopathological diagnosis at the Pathology Department, Faculty of Medicine, Alexandria University. Samples were immediately frozen on dry ice, stored at -70˚C and were transferred on dry ice to the Paterson Institute for Cancer Research in Manchester where they were analysed. DNA was extracted from paired frozen bladder samples (grossly obvious tumour and macroscopically non-involved mucosa obtained as far from the site of tumour as possible) using proteinase K digestion and standard phenol chloroform extraction method (Sambrook et al, 1989) . After taking the tissue for DNA extraction, those samples that were large enough were fixed in 4% buffered formaldehyde and processed to paraffin wax. Representative haematoxylin and eosin stained sections were examined microscopically to confirm the presence of tumour, and to assess the percentage of tumour cells. All cases selected showed at least 40% neoplastic cells amongst fibrous and muscular tissues.
Immunohistochemical analysis of MLH1 and MSH2 proteins
36 analysable samples (24 TCC and 12 SCC) were selected from the formalin-fixed, paraffin embedded sections and serial 3 µm thick sections were cut and subbed on APES (3-aminopropyltriethoxysilane from Sigma) coated slides. Sections were deparaffinized through xylene and graded alcohol. The sections were then treated by microwaving to retrieve antigens in 1 litre of 10 mM citrate buffer (pH 6.0) for 30 min at 700 W, and allowed to cool. Endogenous peroxidase activity was blocked by incubating in 1% H 2 O 2 /100% methanol for 30 min. Non-specific protein binding was eliminated by incubation for 30 min at room temperature in 5% normal rabbit serum (Dako). Sections were incubated overnight at 4˚C with the primary antibody at a dilution of 5 µg ml -1 and 10 µg ml -1 of mouse monoclonal antihuman MLH1 and MSH2 immunoglobulins, respectively (PharMingen). Sections were then incubated with biotinylated rabbit anti-mouse antibody (Dako). Binding sites were visualized using standard avidin-biotin complex method (Hsu et al, 1981) . Sections were counterstained with propidium iodide 2.5 µg ml -1 (Sigma). Positive controls consisting of sections of human colon and negative controls, in which TBS was used instead of primary antibody, were included with every batch. Initially, samples were subjectively screened and this was followed by analysis of 5-10 fields (depending on the section size) using Lucia G image analysis software package which automates data collection. The negative control section for each sample was used to set a threshold above which staining in the immune-stained sections was defined by the analysis system as positive. Thus any background staining was excluded. The total number of tumour cells was determined in the analysed fields by applying a series of semi-automated steps which counts positive-staining cells then adds this number to the negative-staining tumour cells which are counted by virtue of their propidium iodide fluorescence due to lack of the quenching effect of the DAB in the unstained cells. The image analysis thus provides a measure of the total and the positive-stained cells from which the percentage positivity is calculated.
Microsatellite analysis at hMSH2 and hMLH1 loci
A PCR-based method was used to assess allellic loss and/or alterations occurring at loci which lie within, or in close proximity to, MSH2 (2p16) and MLH1 (3p21) genes. Three dinucleotide microsatellite repeats on chromosome 2p16 (D2S123, D2S391, D2S119) and 3p21 (D3S1612, D3S1611, D3S1561) were used. Primer sequences were taken from the 1993-94 Genethon human genetic linkage map (Gyapay et al, 1994) .
PCR amplification was carried out in a 10 µl reaction mix using standard microsatellite analysis PCR method (Varley et al, 1999) . Annealing temperature for D3S1611 marker was adjusted at 62˚C rather than 56˚C to eliminate non-specific bands. Products were separated on 6% denaturing polyacrylamide sequencing gels (National Diagnostics) and dried before exposure overnight to Fuji RX film at -70˚C. Autoradiographs were scored by 2 independent examiners. Loss of heterozygosity (LOH) was scored when there was complete loss of one allele in an informative sample (i.e. the normal DNA was heterozygous), and allellic imbalance (AI) was scored when there was an observed difference in intensity of the alleles between tumoral and normal DNA. Change in allele size or the appearance of a new band in tumoral DNA was scored as new allele (NA). Only informative samples at any of the loci analysed for each gene were included in the calculation of the frequency of allelic loss.
RESULTS
Immunohistochemical analysis of MSH2 and MLH1 proteins
Immunohistochemical staining of MSH2 and MLH1 showed exclusively nuclear staining in both normal and tumour cells. IHC staining of samples of normal urothelium from non-invovled mucosa obtained from radical cystectomy specimens showed relative homogeneity of expression of MMR proteins ( Figure 1 (1/24, 4%), a large proportion of tumours revealed less than 50% positive-stained nuclei for both MSH2 and MLH1 (69% and 44% respectively).
The number of positively stained cells was determined using a threshold defined by the use of tris-buffered saline in place of the immune serum. A wide range of expression of MMR proteins was observed in both pathologic types of bladder cancer (Figure 3 ). There was no correlation between expression of MSH2 and MLH1
Mismatch repair status and bladder cancer 323
British Journal of Cancer (2001) Table 1 summarizes the findings in the two pathologic types. The coefficient of variation for both proteins was high, confirming the observer-reported intertumoral heterogeneity within TCC and SCC samples. The mean percentage positivity of MSH2 in SCC was observed to be half that of MLH1 in the same pathologic subtype; this proved to be statistically significant (P = 0.02 using Wilcoxon Signed Ranks test) ( Table 1) . It was also observed that the mean percentage positivity of MSH2 in SCC was lower than that in TCC, however this was not found to be statistically significant (P = 0.2 using the Mann-Whitney 2-tailed test) ( Table 1) . The relationship between the bilharzial status and the levels of expression of MLH1 and MSH2 was studied using the Mann-Whitney test and revealed a statistically significant difference in the level of expression of MLH1 but not MSH2 in the schistosomal positive versus negative samples (P = 0.01, 0.9 respectively). The samples were further stratified into TCC and SCC in relation to the bilharzial status and a significant difference was still observed in SCC but not in the TCC group (P = 0.04, 0.15, respectively).
Results of microsatellite analysis
Allelic loss was assessed at the markers flanking hMSH2 on chromosome 2p16 and hMLH1 on 3p21 using microsatellite repeats as close together as possible to detect small regions of deletion (Gyapay et al, 1994; Tomlinson et al, 1996) . Representative autoradiographs of the gels used for scoring in this study are shown in Figure 4 . Tables 2A and 2B along with their corresponding immunohistochemical status expressed as percentage positivity. Complete LOH was infrequently encountered. Only one TCC sample (A21; 1/42 i.e. 2%) of the informative samples revealed LOH at one of the markers on chromosome 2p (D2S123). Two TCC samples revealed LOH at chromosome 3p markers (2/44 (5%)), one sample (A4) revealed LOH at the 3 loci analysed while the other sample (A21), revealed LOH at D3S1612 only. Complete LOH was not detected in any of the SCC samples analysed. The incidence of AI was, however, higher than LOH. This could be due to heterogeneity within the tumour and allelic loss occurring in a subpopulation of tumour cells and therefore would be in agreement with the observed intratumoral heterogeneity in expression of MMR proteins. An alternative explanation is that DNA was extracted from visible tumour tissue allowing contamination by normal cells. The frequency of allelic loss (AI and LOH) at the markers flanking MSH2 and MLH1 genes was higher in SCC (38% for both genes) than in TCC (14% and 18%, respectively), but the difference was not statistically significant using Fisher's Exact test (P = 0.3 and 0.5, respectively). There was no effect of the bilharzial status on the incidence of microsatellite alterations at the studied loci (Fisher's Exact test, P = 1).
Allelic imbalance and LOH occurred at markers compatible with the involvement of hMSH2 and hMLH1 genes. AI was detected in the furthest marker studied on chromosome 3p21 in sample H22, however, the IHC finding supported the possibility of involvement of MLH1 in a sub-population of these tumours as the percentage positivity was 42%. Samples that were found to be negative for expression of MSH2 (H12, H22) and MLH1 (H13) did not reveal AI at the flanking microsatellite loci, this could be due to the fact that those samples were non-informative at the studied loci or due to another mechanism of mutation of the involved MMR gene. Sample A4 showed LOH at loci flanking MLH1, and whilst IHC showed a high percentage positivity (89%) for this protein, the intensity of staining was very faint. This may suggest a structural alteration in the expressed protein with reduced affinity for the antibody rather than a technical problem as this sample stained very strongly for MSH2. There was no observed difference in the means of the percentage positivity of expression of MMR proteins in relation to the occurrence of alterations at the loci flanking each or both of the genes (Table 3) . Thus, the two methods of analysis independently detected possible alterations in structure and/or expression of MSH2 and MLH1 genes.
The appearance of a new allele or shift of an existing allele (NA) was detected in two samples. One of them (A21) revealed NA at both 2p16 and 3p21 indicating the presence of a potential mutator phenotype in this tumour which also showed LOH at one of the loci flanking both hMSH2 and hMLH1. To exclude the possibility of PCR contamination or crossing of samples, DNA was again extracted from the original tissues of this sample (tumour and mucosa) and the results were confirmed. Unfortunately, tumour tissue was not available to study the expression of MMR proteins in this sample. The samples analysed in this study were all advanced bladder cancer (at least stage T2 and grades 2 and 3), so it was not possible to assess MMR status in the early stages of bladder cancer from the cohort studied.
DISCUSSION
Earlier studies have suggested that MMR deficiency results in an increased rate of spontaneous mutation, giving the hallmark of a mutator phenotype (Cox, 1973 (Cox, , 1976 . MSI serves as a useful marker of the mutator phenotype that is characteristic of HNPCC and has been attributed to mutations in one of several MMR genes including hMSH2, hMLH1, hPMS1 and hPMS2 Bronner et al, 1994; Fishel et al, 1994; Nicolaides et al, 1994; Papadopoulos et al, 1994) . MSI has been described in a variety of sporadic cancers, such as colon (Thibodeau et al, 1993) , endometrium (Risinger et al, 1993) pancreas and stomach (Han et al, 1993) and prostate (Uchida et al, 1996) . Previous studies have also reported a high frequency of MSI in bladder cancer Steiner et al, 1997; Mourah et al, 1998) . The finding of MSI in a varying proportion of sporadic cancers suggests that the same type of genetic defects in MMR genes that underlie HNPCC can occur somatically in some sporadic cancers including bladder cancer. However, the proportion of sporadic tumours in which MMR genes have been inactivated has not yet been clearly established (Kane et al, 1997) . This might be due to the fact that the methods available for detecting mutations in these genes are laborious, and no single method is capable of detecting all the types of mutations that could exist. This is particularly problematic when tumour samples are analysed because of the contamination of tumour cells with normal tissue in such samples and also due to the fact that the complete spectrum of mutations and modes of inactivation applicable to the analysis of these genes is not currently known (Kane et al, 1997) . In a clinical setting, the use of IHC appears to offer a relatively convenient and rapid method for prescreening tumours for defects in the expression of mismatch repair genes . In the present study alterations in hMSH2 and hMLH1 were determined in TCC and SCC of the bladder using quantitative immunohistochemistry and PCR-based microsatellite analysis methods. IHC analysis showed nuclear localization of staining as reported in previous studies (Lim et al, 1996; Thibodeau et al, 1996; Fink et al, 1997) . Immunostaining of normal urothelium revealed a relatively homogeneous staining of almost all cells as shown in Figure 1 . This is the first report of the pattern of staining of the normal urothelium for these MMR proteins. Intratumoral heterogeneity was observed in the majority of samples. Intratumoral heterogeneity in MLH1 and MSH2 gene alterations has previously been reported by Habano et al (1998) in sporadic colorectal cancer using a sensitive technique for allelic loss detection in different crypts within the same tumour after microdissection. This is therefore in agreement with our findings using immunohistochemistry, which has the benefits of being simpler and more convenient. Metaplastic squamous epithelium showed MSH2 and MLH1 staining of the basal cells and most of the prickle cell layer which is comparable to that previously reported for MSH2 staining of the squamous epithelial lining of the oesophagus and MSH2 and MLH1 staining of the oral mucosa (Leach et al, 1996 and Lo Muzio et al, 1999, respectively) .
The absence of MLH1 and MSH2 immunostaining was previously correlated with the presence of mutation in the corresponding gene in sporadic colon cancer . Such complete absence of expression of MSH2 and MLH1 was infrequently encountered in the present study. However, a large proportion of tumours revealed a percentage positivity of less than 50% for MSH2 and MLH1 (69% and 44%, respectively). The statistically significant lower level of expression of MSH2 in comparison to MLH1 in SCC suggests the possible greater involvement of MSH2 than MLH1 in SCC tumorigenesis and/or progression. The statistically significant difference in the expression of MLH1 in relation to the bilharzial status might suggest a possible role of schistosomiasis in altering the expression of MLH1 in SCC, however this should be further investigated.
In HNPCC, defective MMR is a very early event (Parsons et al, 1995) , while in sporadic non-small cell lung carcinoma it has been suggested that defective MMR is a later event related to lung tumour progression (Wieland et al, 1996) . The present study suggests that MMR deficiency in bladder cancer is likely to occur during tumour progression rather than as an initiating event since the majority of the samples analysed revealed intratumoral heterogeneity in expression of MMR proteins rather than complete loss in all cells of the tumour. The present study involved only advanced stages (at least T2) and advanced grades (2 and 3) of bladder cancer. In this patient group it was therefore not possible to correlate the MMR involvement with tumour progression. The observed intertumoral variation in the expression of these proteins might have prognostic implications regarding outcome or response to therapy. Jin et al (1999) suggested that reduction in expression of MSH2 in TCC of the bladder might be useful in predicting recurrence.
Tumour suppressor and MMR genes share the requirement for homozygosity at the cellular level and somatic deletion is a common event in both (Hemminki et al, 1994) . This second mutational step may be revealed as LOH, which was previously reported at the hMLH1 locus in HNPCC (Hemminki et al, 1994) as well as at hMLH1 and hMSH2 loci in sporadic colorectal cancers (Tomlinson et al, 1996; Benachenhou et al, 1998b) , in non-small cell lung cancer (Benachenhou et al, 1998a) and in breast cancer (Benachenhou et al, 1999) . Christensen et al (1998) reported the occurrence of LOH at microsatellites located close to hMSH2 and hMLH1 and suggested a possible role of these genes in causing profound MSI in bladder cancer. Allelic loss at 3p was previously reported by Rosin et al (1995) and Li et al (1996) which may suggest involvement of hMLH1 in TCC of the bladder. However these studies analysed only TCC and did not include other methods of analysis to confirm hMLH1 involvement. In the present study, allelic loss was studied at loci (D2S123, D2S391 and D2S119) which are known to be linked to hMSH2 . D3S1611 is known to lie within an intron of hMLH1 . Benachenhou et al (1998a) found that the shortest region of overlapping deletions for 3p21 was delimited by D3S1561 and D3S1612. Allelic loss (LOH or AI) was detected in TCC (14% on 2p16 and 18% on 3p21) and in SCC (38% on 2p16 and 38% on 3p21). However, the frequency of allelic loss in the present study should be considered conservative since DNA was not extracted by microdissection and hence some allelic losses could have been masked by contaminating material from normal cells. The frequency of allelic loss at MLH1 in TCC (18%) was similar to that found in sporadic colorectal cancer (17%; Benachenhou et al, 1998b and 16%; Tomlinson et al, 1996) . Whereas in SCC the frequency of allelic loss at MLH1 was higher (38%), which was comparable with that detected in breast cancer (46%; Benachenhou et al, 1999) and non-small cell lung cancer (43%; Wieland et al, 1996) . The frequency of MSH2 allelic loss in TCC detected in this study (14%) was comparable to that detected in non-small cell cancer (11.5%; Benachenhou et al, 1998a) and also in sporadic colorectal cancer (15%; Benachenhou et al, 1998b) . A higher frequency of allelic loss at MSH2 was detected in SCC of the bladder (38%). This together with the finding of a low mean percentage positivity of expression of MSH2 in this pathologic type points to the possibility of a contributing role of MSH2 gene in the pathogenesis of SCC of the bladder.
Other alterations such as small deletions, point mutations, gene rearrangements or DNA cytosine methylation, if they also cause inactivation of both copies of these genes, would escape detection by this PCR based allelic loss analysis method. Therefore, IHC analysis was used to detect samples with deficiency in MMR that was not detected by allelic loss analysis. H12 and H22 lacked expression of MSH2 and H13 lacked MLH1 expression, even though they had no evidence of LOH/AI of the corresponding gene. This may be explained by the fact that MMR genes have no mutational hot spots and lack of expression can occur without detectable mutations . DNA methylation has been reported to be a mode of hMLH1 gene inactivation in sporadic colon and gastric carcinoma (Kane et al, 1997 and Leung et al, 1999, respectively) . A similar mechanism of inactivation by promotor methylation, or possibly by another mechanism of mutation might be responsible for the lack of expression of MMR proteins in the present samples. The samples scored as AI did display reduced expression of the corresponding MMR gene in the majority of cases, however there were exceptions. Sample A34 showed AI at microsatellite loci flanking hMLH1, yet expressed high levels of the protein, this however does not exclude the possibility of functional disturbance of the expressed protein and another explanation may be that the structural alteration may have not involved the antibody recognition sites. Also, although sample A4 revealed LOH at all loci on chromosome 3p and whilst the percentage positivity for expression of MLH1 was 89%, the intensity of staining was very low, suggesting abnormal expression. As shown in Table 3 there was no relationship between the expression (percentage positivity) of the MMR proteins and the occurrence of microsatellite alterations at the corresponding chromosome location. This suggests that the two methods of analysis were useful in determining changes that would not have been detected by either of them alone.
In conclusion, this study reveals the occurrence of alterations in the structure and expression of DNA mismatch repair genes and suggests the possibility of involvement of these genes in tumorigenesis and/or progression of TCC and SCC of the bladder. IHC offers a convenient and a rapid method for prescreening tumours for defects in mismatch repair genes, but might not exclude the structural and functional alterations of these proteins. Further extensive studies would be required to establish whether or not in bladder cancer and in other tumour types IHC may indeed be a more reliable diagnostic test for MMR involvement. To the best of our knowledge, this is the first study to demonstrate an involvement of hMLH1 in TCC and SCC and of hMSH2 in SCC of the bladder.
